AbbVie: Innovating After Humira's Exit
Cashu Finance·5 min read

TL;DR
- AbbVie is transforming post-Humira by focusing on innovative therapies.
- The company's revenue is significantly driven by SKYRIZI and RINVOQ.
- AbbVie aims for future growth through strategic advancements like ABBV-466.
AbbVie Inc. (ABBV) is navigating a pivotal transformation in the biopharmaceutical landscape, emerging from the shadows of its once-flagship product, Humira. As the patent expired on Humira, which had not only generated substantial revenue but had also defined AbbVie's brand for over a decade, the company has turned its focus toward innovative treatments and strategic enhancements in its product offerings to secure its position in a competitive marketplace. With the introduction of biosimilars threatening to erode Humira's legacy, AbbVie has sought to redefine its identity through robust product development and strategic acquisitions.
The Decline of a Legacy Product
Humira served as the cornerstone of AbbVie’s business, accounting for a significant portion of revenue through its wide applicability in treating autoimmune diseases. However, the expiration of Humira’s patent has ushered in a new era characterized by increased competition. Recent reports reveal that Humira's revenue has dropped to $683 million from nearly $1 billion last year, marking a dramatic 30.6% decline. This statistic highlights not only the immediate pressure on AbbVie due to the influx of biosimilars but also the urgent need for the company to pivot and innovate in response to the evolving healthcare environment.
Historically, AbbVie capitalized on Humira’s success by establishing a solid foundation; yet, the loss of exclusivity has necessitated a proactive strategy for revenue generation. Understanding this context is vital as AbbVie gears up for its next chapter, which could be characterized by diversification and the development of new targeted therapies. To that end, AbbVie has looked to its newer products, RINVOQ and SKYRIZI, which have emerged as powerful drivers of growth for the company.

